How many drugs treat Adenocarcinoma of pancreas?

Drug Landscape tracks 10 marketed treatments for Adenocarcinoma of pancreas (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/adenocarcinoma-of-pancreas.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Adenocarcinoma of pancreas — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Adenocarcinoma of pancreas (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Adenocarcinoma of pancreas, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Tarceva	erlotinib	Osi Pharms	Kinase Inhibitor	Epidermal growth factor receptor	2004-01-01
Camptosar	onivyde	Pfizer	Topoisomerase Inhibitor	Acetylcholinesterase	1996-01-01
Gemzar	Gemcitabine Hydrochloride	Accord Hlthcare	Nucleoside metabolic inhibitor	Ribonucleotide reductase; DNA incorporation	1996-01-01
Camptosar	Irinotecan Hydrochloride	Pfizer	Topoisomerase Inhibitor	Acetylcholinesterase	1996-01-01
Gemzar	gemcitabine	Accord Hlthcare	Nucleoside Metabolic Inhibitor	DNA polymerase (alpha/delta/epsilon)	1996-01-01
Camptosar	irinotecan	Pfizer	Topoisomerase Inhibitor	topoisomerase I	1996-01-01
Mitozytrex	MITOMYCIN	Kyowa Kirin Co., Ltd.	Alkylating Drug [EPC]	Indoleamine 2,3-dioxygenase 1	1981-01-01
Carac	5-fu	Spectrum Pharms	Nucleoside Metabolic Inhibitor	Aromatase	1962-01-01
Carac	fluorouracil	Extrovis	Nucleoside Metabolic Inhibitor [EPC]	Aromatase	1962-01-01
Gemcitabin	Gemcitabin	Cancer Institute and Hospital, Chinese Academy of Medical Sciences		UMP-CMP kinase, Deoxycytidine kinase, Ribonucleoside-diphosphate reductase large subunit

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 3 drugs in Adenocarcinoma of pancreas
Accord Hlthcare · 2 drugs in Adenocarcinoma of pancreas
Extrovis · 1 drug in Adenocarcinoma of pancreas
Kyowa Kirin Co., Ltd. · 1 drug in Adenocarcinoma of pancreas
M.D. Anderson Cancer Center · 1 drug in Adenocarcinoma of pancreas
Osi Pharms · 1 drug in Adenocarcinoma of pancreas
Spectrum Pharms · 1 drug in Adenocarcinoma of pancreas
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 drug in Adenocarcinoma of pancreas

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Adenocarcinoma of pancreas:

Cite this brief

Drug Landscape (2026). Adenocarcinoma of pancreas — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/adenocarcinoma-of-pancreas. Accessed 2026-06-10.

Adenocarcinoma of pancreas full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing